Company intelligence / Profile preview

PharmaJet

Ownership: Private
Development stage: Other

Overview

PharmaJet’s needle-free injection systems have demonstrated improved immunogenicity and patient preference compared to traditional needle-syringe methods. Their technology has been used in over eighty studies with more than fifty development partners globally. Clinical results include positive interim Phase 2 data in cervical cancer with Nykode Therapeutics’ DNA vaccine delivered by PharmaJet’s system and the world’s first approved human DNA COVID‑19 vaccine delivered exclusively with their Tropis device in India.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Nucleic acid-based vaccines (DNA, mRNA)Small molecules (as injectables)Biologics/vaccines in general
Industry: Therapeutic Medical Devices

Partnerships

Nykode TherapeuticsImmunomic TherapeuticsZydus LifesciencesScancell Holdings plcmultiple pharmaceutical and academic collaborators (>50 development partners)

Beyond the preview

Go deeper on PharmaJet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaJet.